GlycoMimetics Q1 2025 10-Q Filed
Ticker: CBIO · Form: 10-Q · Filed: May 14, 2025 · CIK: 1253689
| Field | Detail |
|---|---|
| Company | Glycomimetics INC (CBIO) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
GlycoMimetics Q1 2025: Assets $64.5M, Liabilities $64.4M. Tight balance sheet.
AI Summary
GlycoMimetics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $64.5 million and total liabilities of $64.4 million as of March 31, 2025. This filing covers the first quarter of 2025 and provides financial updates for the company.
Why It Matters
This filing provides a snapshot of GlycoMimetics' financial health and operational status for the first quarter of 2025, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company has very little net assets, indicating a high degree of financial risk.
Key Numbers
- $64.5B — Total Assets (As of March 31, 2025, indicating the company's total resources.)
- $64.4B — Total Liabilities (As of March 31, 2025, representing the company's total obligations.)
Key Players & Entities
- GlycoMimetics Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- $64,532,091 (dollar_amount) — Total assets as of March 31, 2025
- $64,483,958 (dollar_amount) — Total liabilities as of March 31, 2025
FAQ
What was GlycoMimetics' net income or loss for the first quarter of 2025?
The provided excerpt does not contain specific net income or loss figures for the first quarter of 2025. It focuses on balance sheet items and general filing information.
What are the primary business segments or products of GlycoMimetics?
The filing indicates GlycoMimetics, Inc. is in the 'Pharmaceutical Preparations' industry (SIC 2834), but specific product details or segments are not detailed in this excerpt.
Did GlycoMimetics engage in any significant financing activities during the first quarter of 2025?
The filing mentions 'AtMarketOffering2022Member' for the period of January 1, 2025, to March 31, 2025, suggesting potential equity financing activities.
What is the company's cash position as of March 31, 2025?
The excerpt does not explicitly state the cash position. It provides total assets and liabilities, but not a breakdown of current assets like cash.
Are there any significant changes in equity accounts compared to the previous quarter or year?
The filing lists various equity accounts like 'CommonStockMember', 'RetainedEarningsMember', and 'AdditionalPaidInCapitalMember' for multiple periods, including March 31, 2025, and prior dates, implying data for comparison is available within the full document.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding GLYCOMIMETICS INC (CBIO).